Femasys Inc. (NASDAQ:FEMY) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 18,900 shares, a growth of 293.8% from the September 15th total of 4,800 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 77,400 shares, the short-interest ratio is presently 0.2 days.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC acquired a new stake in Femasys in the 2nd quarter worth approximately $105,000. Millennium Management LLC bought a new position in Femasys in the 2nd quarter worth approximately $109,000. Envestnet Asset Management Inc. bought a new position in Femasys in the 2nd quarter worth approximately $184,000. Maven Securities LTD bought a new stake in shares of Femasys during the second quarter valued at approximately $184,000. Finally, PVG Asset Management Corp bought a new stake in shares of Femasys during the second quarter valued at approximately $344,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.
Shares of NASDAQ FEMY opened at $7.25 on Thursday. Femasys has a one year low of $6.50 and a one year high of $13.75. The business’s 50-day simple moving average is $7.14.
FEMY has been the topic of a number of research analyst reports. Zacks Investment Research lowered Femasys from a “buy” rating to a “hold” rating in a report on Tuesday. Chardan Capital started coverage on Femasys in a report on Tuesday, July 13th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Jonestrading initiated coverage on Femasys in a report on Tuesday, July 13th. They set a “buy” rating and a $8.45 target price on the stock.
Femasys Inc, a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
Further Reading: 52-week highs
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.